University of Oslo

Vaccibody As

Universitetet I Oslo

Albumedix Limited

Other

Tillotts Pharma Ag

Novozymes Biopharma Dk A/s

Dynal As

Nextera As

Universitetet | Oslo

Novozymes Biopharma Dic A/s

Albumedix A/s

Nykode Therapeutics Asa

Inger Sandlie

Jan Terje Andersen

Bjarne Bogen

Esben Peter Friis

Jason Cameron

Andrew Plumridge

Geir Age Loset

Darrell Sleep

Terje Frigstad

Agnete Brunsvik Fredriksen

Malin Bern

Stian Foss

Esther Maria Furrer

Karen Ann Delahay

Geir Åge Løset

Terje Michaelsen

Leslie Evans

Steven Athwal

Nicolay Rustad Nilssen

Elizabeth Allan

Agnete Fredriksen Brunsvik

Bjorn Dalhus

Sigbj&oslash;rn Fossum

Siri Mjaaland

Ingunn B Rasmussen

Elin Lunde

Sebastian Berge-Seidl

Geir Age Løset

Geir ÅGe LØSET

Terje Jan Andersen

The present invention relates to antibodies which bind to TNFα and exhibit modified FcRn-binding. The antibodies of the invention have good effector functions and/or pharmacokinetic properties.

Antibody variants

The present invention relates to compositions and methods for antibody-mediated therapy. In particular, provided herein are engineered immunoglobulins with altered half-life.

Engineered immunoglobulins with altered FcRn binding

The present invention provides a vector construct comprising the following components: (i) a sequence encoding a signal peptide which directs proteins into the Tat secretory pathway; and (ii) a sequence encoding a fluorophore fused to a sequence encoding a pVIII phage coat protein. Nucleic acid molecules comprising components (i) and (ii) are also provided, together with phage particles comprising such vectors or nucleic acid molecules and expressing a fluorophore-pVIII fusion protein on the surface. Methods for producing such fluorescent phage particles are also provided.

Vector construct

The present invention relates to albumin variants with an improved affinity for the neonatal Fc receptor (FcRn) and uses thereof, and in particular to the use of such albumin variants as carriers for immunogens. In some embodiments, the present invention relates to vaccines (e.g., vaccines for mucosal delivery) comprising albumin/immunogen fusion proteins.

Albumin variants and uses thereof

The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.

Albumin variants

The present invention relates to vectors, methods and systems for polypeptide display and selection. Specifically, the present invention relates to vectors, methods, and systems for multivalent phage display using pIX protein of filamentous phage and helper phage.

Multivalent phage display systems and methods

The application discloses albumin derivatives comprising or consisting of domain III and at least one further domain wherein the derivative or variant is not a naturally occurring albumin derivative or variant. The derivatives may be used in conjugates and fusion polypeptides.

Albumin derivatives and variants

Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.

Modified antibody

The present invention relates to disulphide bond stabilized recombinant MHC class II molecules. In particular, the present invention provides a recombinant MHC class II molecule, which comprises: (i) all or part of the extracellular portion of an MHC class II &#x3b1; chain; (ii) all or part of the extracellular portion of an MHC class II &#x3b2; chain; wherein (i) and (ii) provide a functional peptide binding domain and wherein (i) and (ii) are linked by a disulphide bond between cysteine residues located in the &#x3b1;2 domain of said &#x3b1; chain and the &#x3b2;2 domain of said &#x3b2; chain, wherein said cysteine residues are not present in native MHC class II &#x3b1;2 and &#x3b2;2 domains. Methods of producing these molecules in prokaryotic systems and various uses of these molecules form further aspects.

Disulphide bond-stabilized functional soluble MHC class II heterodimers

Variants of a parent albumin having altered plasma half-life compared with a parent albumin are described. Fusion polypeptides and conjugates including the variant albumin are also described. Embodiments include, but are not limited to, a polypeptide which is a variant of albumin, including one or more alterations at one or more positions corresponding to 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 and 120 in SEQ ID NO: 2.

Growing community of inventors

Oslo, Norway

Inger Sandlie